Pharmacoeconomic research partnerships should be attractive to industry, OTA's Wagner says.
PHARMACOECONOMIC RESEARCH PARTNERSHIPS -- WITH NO VETO FOR MARKETERS -- are in "pharmaceutical companies' best interests," Office of Technology Assessment Senior Associate Judith Wagner maintained in a presentation to the Biotechnology Industry Organization annual meeting May 24 in San Francisco. Drug companies will increasingly find it to their advantage to "help fund independent buyer-led studies of cost-effectiveness analyses," in light of recent FDA suggestions that pharmacoeconomic claims by manufacturers will likely require two adequate well-controlled trials, Wagner suggested.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth